Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity

Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity

We seek to further addresss the questions posed by Moseson et al. regarding whether any residual crystal level, size, or characteristic is acceptable in an amorphous solid dispersion (ASD) such that its stability, enhanced dissolution, and increased bioavailability are not compromised. To address th...

Full description

Bibliographic Details
Main Authors: Daniel A. Davis, Jr, Dave A. Miller, Supawan Santitewagun, J. Axel Zeitler, Yongchao Su, Robert O. Williams, III
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:International Journal of Pharmaceutics: X
Subjects:
Residual crystallinity
Seed crystallinity
Amorphous solid dispersion
Degradation
Bioavailability enhancement
KinetiSol processing
Online Access:http://www.sciencedirect.com/science/article/pii/S2590156721000219

Internet

http://www.sciencedirect.com/science/article/pii/S2590156721000219

Similar Items